AB 1682 adds parallel coverage mandates to the Health and Safety Code and Insurance Code, and a benefits provision to the Welfare & Institutions Code, requiring that health care service plan contracts and health insurance policies issued, amended, delivered, or renewed on or after January 1, 2027, cover scalp cooling when prescribed by a health care provider in connection with chemotherapy for persons with cancer. The bill also directs the Department of Health Care Services to expand the Medi‑Cal benefit schedule to include scalp cooling, but only to the extent federal financial participation is available and necessary federal approvals are obtained.
This is a narrowly focused benefit mandate aimed at reducing chemotherapy‑related alopecia. It creates immediate compliance obligations for California‑regulated insurers and plans, potential new benefit entitlement for Medi‑Cal enrollees (contingent on CMS), and raises implementation questions about what the mandated coverage must include (devices, staffing, disposables) and how cost‑sharing and utilization controls may apply.
At a Glance
What It Does
The bill requires California‑regulated health care service plans and insurers to cover scalp cooling when prescribed in connection with chemotherapy for cancer patients for contracts or policies issued, amended, delivered, or renewed on or after January 1, 2027. It directs Medi‑Cal to add scalp cooling to its schedule of benefits contingent on federal financial participation and approvals.
Who It Affects
DMHC‑regulated health care service plans, DOI‑regulated insurers, Medi‑Cal (State Department of Health Care Services), oncology providers and infusion clinics that offer or refer for scalp cooling, device manufacturers and vendors, and patients receiving chemotherapy in California.
Why It Matters
The bill makes an evidence‑based supportive oncology procedure an explicitly covered benefit under state‑regulated plans and seeks to extend that coverage to Medi‑Cal recipients, shifting decisions about access and payment from clinicians and clinics to insurers and the state Medicaid program. It also creates compliance and operational work for payers, providers, and Medi‑Cal administrators.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 1682 inserts three new statutory provisions into California law to force coverage for scalp‑cooling systems and services when a health care provider prescribes them as part of chemotherapy care for people with cancer. For private coverage, the bill applies to both health care service plans regulated under the Knox‑Keene Act and to insurers regulated by the Department of Insurance; the operative trigger is any contract or policy issued, amended, delivered, or renewed on or after January 1, 2027.
For Medi‑Cal, the bill instructs the Department of Health Care Services to expand the Medi‑Cal benefits schedule to include scalp cooling, but only to the extent federal matching funds are available and after any needed federal approvals are secured. That makes Medi‑Cal coverage conditional rather than automatic: the state must still obtain CMS sign‑off and determine whether the service fits within federal Medicaid benefit rules and available appropriations.The bill ties enforcement to existing regulatory frameworks.
Willful violations of the Knox‑Keene Act are criminalized, so plan noncompliance could trigger serious sanctions under the Health and Safety Code; insurers remain subject to Department of Insurance oversight and market conduct enforcement. The statute does not itself define every operational detail — for example, it does not enumerate whether coverage must include device rental or purchase, staffing and chair time, disposables, or ancillary nursing expenses — leaving significant implementation decisions to regulators, payers, and providers.Finally, AB 1682 contains the typical state‑mandate and reimbursement language: it creates a state‑mandated local program because of the criminal exposure under Knox‑Keene, but it also states that no state reimbursement is required for reasons set out in the bill.
Practically, stakeholders should expect plan benefit design work, prior authorization protocols, billing code negotiations, and potential gaps between stated coverage and on‑the‑ground access during the early implementation period.
The Five Things You Need to Know
Effective trigger: Coverage obligations apply to contracts or policies issued, amended, delivered, or renewed on or after January 1, 2027.
Scope of coverage: Plans and insurers must cover 'scalp cooling, as prescribed by a health care provider in connection with chemotherapy for persons with cancer' — the bill ties coverage to a clinician prescription.
Medi‑Cal conditionality: The state will add scalp cooling to the Medi‑Cal benefits schedule only if federal financial participation is available and required federal approvals (e.g.
CMS sign‑off) are obtained.
Enforcement and penalties: For health care service plans, noncompliance intersects with the Knox‑Keene Act; a willful violation of those provisions is treated as a crime, creating heightened legal exposure for plans.
Drafting gaps: The bill does not specify benefit details (device rental vs. provider fee vs. disposables), allowables for cost‑sharing, or explicit implementation timelines beyond the Jan 1, 2027 trigger.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Plan‑contract coverage requirement for scalp cooling
This new Health and Safety Code section imposes the requirement on health care service plans licensed under Knox‑Keene to provide coverage for scalp cooling when prescribed in connection with chemotherapy for cancer patients, for contracts issued, amended, delivered, or renewed on or after January 1, 2027. Practical implications include updating Evidence of Coverage documents, medical necessity and prior‑authorization criteria, provider payment rates, and network arrangements for clinics that administer scalp cooling. Because Knox‑Keene enforcement can include criminal penalties for willful violations, plan compliance teams should treat this as a high‑priority benefit change with potential regulatory and criminal oversight consequences.
Insurer coverage requirement mirroring the plan mandate
This provision creates a parallel mandate for health insurers regulated by the Department of Insurance to cover scalp cooling prescribed in connection with chemotherapy for policies issued, amended, delivered, or renewed on or after January 1, 2027. The Department of Insurance will enforce compliance through its market conduct and regulatory tools rather than Knox‑Keene criminal mechanisms; however, insurers must still revise policy forms, actuarial assumptions, and provider contracting practices. The statute does not carve out federal ERISA‑governed self‑funded employer plans, which remain governed by federal law.
Medi‑Cal benefit expansion, contingent on federal funding/approval
This Welfare & Institutions Code addition directs the Department of Health Care Services to expand Medi‑Cal benefits to include scalp cooling when prescribed in connection with chemotherapy, subject to the availability of federal financial participation and necessary federal approvals. The contingency means the state must obtain CMS approval (if required) and secure matching funds; the provision creates authority rather than an unconditional entitlement. Operationally, DHS will need to issue State Plan Amendment(s) or waivers as appropriate, set billing codes and rates, and decide whether coverage applies in managed care, fee‑for‑service, or both.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Cancer patients receiving chemotherapy who wish to reduce treatment‑related hair loss: the bill creates an explicit entitlement to scalp‑cooling services when prescribed, increasing the likelihood of payer reimbursement for an otherwise out‑of‑pocket supportive service.
- Medi‑Cal beneficiaries with cancer (conditional): if CMS approval and federal funds are obtained, low‑income Californians on Medi‑Cal would gain coverage for scalp cooling that they may not currently have.
- Manufacturers and vendors of scalp‑cooling systems: a statutory coverage mandate expands the addressable market and strengthens negotiating leverage with payers and providers.
- Oncology clinics and infusion centers offering scalp cooling: clearer reimbursement pathways could support adoption or expansion of scalp‑cooling services and stabilize revenue streams tied to those services.
- Oncologists and prescribing clinicians: they gain a predictable coverage option to offer patients concerned about alopecia, reducing the need to counsel on self‑pay alternatives.
Who Bears the Cost
- California‑regulated health plans and insurers (DMHC and DOI‑regulated): they must absorb the direct costs of covering scalp cooling or adjust premiums/benefit designs, update contracts, and implement utilization management processes.
- State Medi‑Cal program and budget: expanding benefits, even with federal match, requires state administrative effort and potential General Fund commitments if federal funding is limited or conditioned.
- Oncology clinics that must invest in equipment or staffing: if clinics choose to provide onsite scalp‑cooling devices, they may face capital outlays, training costs, and billing system changes before reimbursement is routine.
- Payers and providers administering prior authorization and utilization controls: operational costs will rise due to new medical necessity criteria, claims edits, and potential appeals.
- Patients may still face cost‑sharing or access hurdles: although the bill requires coverage, it does not eliminate copayments, coinsurance, or nonfinancial barriers (appointment availability, travel), which could shift costs to patients in practice.
Key Issues
The Core Tension
The bill pits a patient‑centered objective — broadening access to a supportive therapy that can reduce chemotherapy‑associated alopecia — against the operational, actuarial, and budgetary costs of adding a new mandated benefit, all while leaving key implementation questions unresolved and relying on federal Medicaid processes for Medi‑Cal expansion.
AB 1682 mandates coverage on paper but leaves critical implementation details unspecified. The statute ties coverage to a clinician's prescription and to the phrase 'scalp cooling,' but it does not enumerate whether that includes the capital cost of devices, per‑session rental fees, nursing time, supplies, or facility charges.
Payers and providers will need to negotiate coding and billing practices and decide how to classify and reimburse these elements. The result may be a period in which plans nominally cover scalp cooling yet deny payment for key components, prompting appeals and administrative disputes.
The Medi‑Cal provision is explicitly conditional on federal financial participation and approvals, which transfers substantial implementation risk to CMS review and state budget decisions. Moreover, California cannot compel ERISA‑governed self‑funded employer plans to provide this benefit, creating a patchwork of access across insured populations.
Enforcement differences between DMHC (where willful Knox‑Keene violations can be criminal) and DOI (administrative market conduct oversight) add complexity: plans and insurers face different compliance incentives and enforcement risk profiles. Finally, the bill does not address utilization management limits such as clinical eligibility by chemotherapy regimen, timing, or expected efficacy, leaving open the possibility that narrow medical necessity criteria or prior authorization requirements will constrain access despite the coverage mandate.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.